Year None2022202120202019201820172016 September 30, 2022 Medicenna Extends Period to Exercise Certain Warrants Go to September 28, 2022 Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study Go to September 22, 2022 Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022 Go to September 21, 2022 Medicenna Announces Results of Annual Meeting of Shareholders Go to September 13, 2022 Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial Go to September 8, 2022 Medicenna to Present at Investor and Scientific Conferences in September Go to Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
September 28, 2022 Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study Go to
September 22, 2022 Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022 Go to
September 13, 2022 Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial Go to
